Description
Data Sheet
| Amino acid sequence | LGSFVHCEPC DEKALSMCPP SPLGCELVKE PGCGCCMTCA LAEGQSCGVY TERCAQGLRC LPRQDEEKPL HALLHGRGVC LNEKSYREQV KIERDSREHE EPTTSEMAEE TYSPKIFRPK HTRISELKAE AVKKDRRKKL TQSKFVGGAE NTAHPRIISA PEMRQESEQG PCRRHMEASL QELKASPRMV PRAVYLPNCD RKGFYKRKQC KPSRGRKRGI CWCVDKYGMK LPGMEYVDGD FQCHTFDSSN VE. |
| Antibody Properties | Reconstitute with sterile H20. Mix gently, wash the sides of the vial and wait 30-60 seconds before use. |
| Biological Activity | The ED50, calculated by its ability to inhibit IGF-II induced proliferation of MCF-7. The expected ED50 for this effect is 2500 IU/mg in the presence of 15ng/ml of rHuIGF-II. |
| Description | IGFBP5 Human Recombinant produced in E.Coli is non-glycosylated homodimer containing 2×252 amino acids and having a molecular mass of 28.6kDa. IGFBP5 is purified by proprietary chromatographic techniques. |
| Expression host | Escherichia Coli. |
| Formulation | IBP-5 was lyophilized from a concentrated (1mg/ml) solution containing 10mM sodium Citrate pH-3. |
| Introductionn | This antibody will stain 70% of PHA-activated human T cells (by FACS). 10ul will stain 106 IL-2R positive cells for FACS analysis or sorting. |
| Protein Background | IGFBP5 is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. |
| Purity | Greater than 96.0% as determined by:(a) Analysis by RP-HPLC.(b) Analysis by SDS-PAGE. |
| Reagent Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Reconstitution | 1mg/ml in PBS (after reconstitution). |
| References | Title:Effects of Dietary Carbohydrate Modificationin Persons with the Metabolic Syndrome- A Transcriptomics Approach in Adipose TissuePublication:Department of Clinical Nutrition, Food and Health Research CentreInstitute of Public Health and Clinical NutritionFaculty of Health SciencesUniversity of Eastern Finland Kuopio 2010Link:http://epublications.uef.fi/pub/urn_isbn_978-952-61-0024-1/urn_isbn_978-952-61-0024-1.pdf |
| Solubility | It is recommended to reconstitute the lyophilized Insulin-Like Growth Factor Binding Protein-5 in sterile 18M-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions. |
| Stability | Lyophilized IBP5 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution IGFBP 5 should be stored at 4°C between 2-7 days and for future use below -18°C.For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Please prevent freeze-thaw cycles. |
| Synonyms | IGFBP-5, IBP-5, IGF-binding protein 5. |
| Titer | Antibody is shipped lyophilized at ambient temperature. |
